ArticleThe Journal of infectious diseases2020
Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- Measles seroprevalence among health care professionals during a period of increased transmission: A pilot study in Southern Italy.IJID regions · 2026Article
- Measles seropositivity in previously vaccinated individuals: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Organizational evidence-based practice culture, implementation leadership, and nurses: A bidirectional mediation model.International nursing review · 2025Observational
- A Case Series of Adult Measles from a Tertiary Care Hospital in North India.The American journal of tropical medicine and hygiene · 2025Article
- A systematic review and modelling insights of factors impacting measles vaccine effectiveness, efficacy and immunogenicity.Discover viruses · 2025Review
- Securing long-term immunity: The possible necessity of supplementary measles vaccination.BMC infectious diseases · 2024Article
- Individual and contextual factors associated with measles infection in Malaysia: a multilevel analysis.Osong public health and research perspectives · 2024Article
- Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study.Vaccines · 2024Article
- Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy.Vaccines · 2024Article
- Measles Immunity Status of Greek Population after the Outbreak in 2017-2018: Results from a Seroprevalence National Survey.Vaccines · 2023Article
- A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9.NPJ vaccines · 2023Article
- Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Article
- Two years of on-site influenza vaccination strategy in an Italian university hospital: main results and lessons learned.Human vaccines & immunotherapeutics · 2022Article
- Prevalence and management of rubella susceptibility in healthcare workers in Italy: A systematic review and meta-analysis.Vaccine: X · 2022Article
- Article
- Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.NPJ vaccines · 2022Review
- Article
- Susceptibility towards Chickenpox, Measles and Rubella among Healthcare Workers at a Teaching Hospital in Rome.Vaccines · 2022Article
- Anti-SARS-CoV-2 antibodies among vaccinated healthcare workers: Repeated cross-sectional study.Journal of family medicine and primary care · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLevels of antibodies induced by the measles virus-containing vaccine have been shown to decline over time, but there is no formal recommendation about testing immunized subjects (in particular, healthcare workers [HCWs]) to investigate the persistence of measles immunoglobulin G (IgG).
methodsThis study aims to evaluate the long-term immunogenicity of measles vaccine in a sample of medical students and residents of the University of Bari who attended the Hygiene Department for a biological risk assessment (April 2014-June 2018).
resultsTwo thousand immunized (2 doses of measles-mumps-rubella [MMR] vaccine) students and residents were tested; 305 of these (15%) did not show protective anti-measles IgG. This proportion was higher among subjects who received vaccination at ≤15 months (20%) than in those who received vaccination at 16-23 months (17%) and at ≥24 months (10%) (P < .0001). After an MMR vaccine booster dose, we noted a seroconversion of 74% of seronegative HCWs. The overall seroconversion rate after a second dose (booster) was 93%. No serious adverse events were noted after the booster doses.
conclusionsAn important proportion of subjects immunized for measles do not show a protective IgG titer in the 10 years after vaccination. Our management strategy seems consistent with the purpose of evidencing immunological memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.